Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Aya, Francisco
- dc.contributor.author González Navarro, E. Azucena
- dc.contributor.author Martínez, Clara M.
- dc.contributor.author Carcelero, Esther
- dc.contributor.author Arance, Ana
- dc.date.accessioned 2021-07-14T07:03:41Z
- dc.date.issued 2021
- dc.description.abstract Aim: To evaluate the safety of rechallenge with a different anti-PD-1 antibody after an immune-related adverse event (irAE) that has prompted the discontinuation of anti-PD-1 therapy. Patients & methods: We describe two patients with metastatic melanoma who developed potentially disabling and early irAEs following anti-PD-1 treatment. Therapy was discontinued and toxicities resolved with corticosteroids. Results: Rechallenge switching to an alternative anti-PD-1 antibody did not lead to a new or recurrent irAE. Conclusion: Switching to a different anti-PD-1 antibody when resuming therapy after an irAE might be a safe strategy and warrants further investigation. Structural and biological differences between antibodies might explain the different safety outcomes.
- dc.format.mimetype application/pdf
- dc.identifier.citation Aya F, González-Navarro EA, Martínez C, Carcelero E, Arance A. Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication. Immunotherapy. 2021;13(9):745-52. DOI: 10.2217/imt-2020-0274
- dc.identifier.doi http://dx.doi.org/10.2217/imt-2020-0274
- dc.identifier.issn 1750-743X
- dc.identifier.uri http://hdl.handle.net/10230/48176
- dc.language.iso eng
- dc.publisher Future Science Group
- dc.relation.ispartof Immunotherapy. 2021;13(9):745-52
- dc.rights © 2021 Future Medicine Ltd
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.keyword Anti-PD-1
- dc.subject.keyword Antibody
- dc.subject.keyword Immune checkpoint inhibitors
- dc.subject.keyword Immune-related adverse event
- dc.subject.keyword Immunotherapy
- dc.subject.keyword Melanoma
- dc.subject.keyword Rechallenge
- dc.subject.keyword Switching antibodies
- dc.subject.keyword Toxicity
- dc.title Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/acceptedVersion